What does the drug do?

ILB is a pleiotropic molecule which means it is believed to have multiple effects in the body. Its active component, a patented form of dextran sulphate, targets multiple pathways that are involved in the loss of function and death of neurons, which is characteristic of MND and other neurological diseases. It is administered via a subcutaneous (under-the-skin) injection.

Phase 2

Current status: Awaiting results

The Phase 2 open label trial aimed at investigating the safety and tolerability of ILB enrolled 11 participants. The participants took 2 mg/kg of ILB, by subcutaneous (under the skin) injection once a week for 48 weeks. You can read more about the trial here.

How can I take part in the trial?

Recruiting Sites

This trial is fully recruited and is no longer accepting new participants. 

Latest News

2022

May 2022 - TikoMed announce results from a Swedish trial of ILB that show some improvement in ALSFRS-R scores and decreased levels of biomarkers associated with muscle wasting. Results from the UK trial are expected in 2023. You can find out more here

Last updated: 11/03/2024